| Title: |
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists |
| Authors: |
Goldenberg, Ronald M.; Cheng, Alice Y.Y.; Fitzpatrick, Tess; Gilbert, Jeremy D.; Verma, Subodh; Hopyan, Julia J. |
| Source: |
Stroke ; volume 53, issue 5, page 1813-1822 ; ISSN 0039-2499 1524-4628 |
| Publisher Information: |
Ovid Technologies (Wolters Kluwer Health) |
| Publication Year: |
2022 |
| Description: |
People living with diabetes are at higher risk for stroke and have a poorer prognosis following a stroke event than those without diabetes. Data from cardiovascular outcome trials and meta-analyses indicate that GLP-1RAs (glucagon-like peptide 1 receptor agonists) reduce the risk of stroke in individuals with type 2 diabetes. Accordingly, many guidelines now recommend the addition of GLP-1RAs to ongoing antihyperglycemic regimens to lower the risk of stroke in type 2 diabetes. The current work summarizes evidence supporting the use of GLP-1RAs for stroke reduction in people with type 2 diabetes and offers 2 new resources for neurologists who are considering GLP-1RAs for their patients—a list of frequently asked questions with evidence-based answers on safely initiating and managing GLP-1RAs, and a practical decision-making algorithm to assist in using GLP-1RAs as part of a stroke reduction strategy. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1161/strokeaha.121.038151 |
| DOI: |
10.1161/STROKEAHA.121.038151 |
| Availability: |
https://doi.org/10.1161/strokeaha.121.038151; https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.121.038151 |
| Accession Number: |
edsbas.C0C909E5 |
| Database: |
BASE |